601607 上海医药
午间休市 07-31 11:29:56
资讯
新帖
简况
上海医药(601607.SH)：瑞舒伐他汀依折麦布片(Ⅰ)获得批准生产
智通财经 · 07-30 15:59
上海医药(601607.SH)：瑞舒伐他汀依折麦布片(Ⅰ)获得批准生产
上海医药(601607.SH)：龙虎清凉油经典款等三款产品获加拿大产品许可证
智通财经 · 07-30 15:57
上海医药(601607.SH)：龙虎清凉油经典款等三款产品获加拿大产品许可证
股市必读：上海医药（601607）7月29日董秘有最新回复
证券之星 · 07-30 01:35
股市必读：上海医药（601607）7月29日董秘有最新回复
上海医药：2026年第一季度公司药品CSO业务新承接7个品种的商业化合作
证券日报 · 07-29 20:00
上海医药：2026年第一季度公司药品CSO业务新承接7个品种的商业化合作
上海医药：公司收购上海和黄后，双方整合大品种开发、循证医学研究、中药国际化等核心资源
证券日报 · 07-29 19:58
上海医药：公司收购上海和黄后，双方整合大品种开发、循证医学研究、中药国际化等核心资源
上海医药、君实生物等成立新私募基金 出资额15亿
南方财经网 · 07-28
上海医药、君实生物等成立新私募基金 出资额15亿
上海医药2025年三大业务板块毛利率集体下滑遭问询 公司回复
南方财经网 · 07-27
上海医药2025年三大业务板块毛利率集体下滑遭问询 公司回复
出资3亿，上海医药做LP了
PE星球 · 07-26
出资3亿，上海医药做LP了
每周股票复盘：上海医药（601607）终止丹酚酸A临床试验
证券之星 · 07-26
每周股票复盘：上海医药（601607）终止丹酚酸A临床试验
上海医药（601607）披露参与设立上海上实生物医药产业私募基金暨关联交易进展，7月24日股价下跌1.27%
证券之星 · 07-24
上海医药（601607）披露参与设立上海上实生物医药产业私募基金暨关联交易进展，7月24日股价下跌1.27%
上海医药(02607)：决定终止注射用丹酚酸A的临床试验及后续开发
智通财经 · 07-24
上海医药(02607)：决定终止注射用丹酚酸A的临床试验及后续开发
杨鑫鑫2026年二季度表现，工银精选平衡混合基金季度跌幅3.96%
证券之星 · 07-21
杨鑫鑫2026年二季度表现，工银精选平衡混合基金季度跌幅3.96%
股市必读：上海医药（601607）7月20日董秘有最新回复
证券之星 · 07-21
股市必读：上海医药（601607）7月20日董秘有最新回复
上海医药：双靶点CAR-T产品B019Ⅰ期临床试验正有序推进
证券之星 · 07-20
上海医药：双靶点CAR-T产品B019Ⅰ期临床试验正有序推进
上海医药(601607.SH)下属公司清润养目颗粒获批开展临床试验
智通财经 · 07-20
上海医药(601607.SH)下属公司清润养目颗粒获批开展临床试验
每周股票复盘：XD上海医（601607）上海医药拟出资3亿参与设立生物医药基金
证券之星 · 07-19
每周股票复盘：XD上海医（601607）上海医药拟出资3亿参与设立生物医药基金
上海医药：拟挂牌出售上药益药医药（上海）有限公司41%股权
证券之星 · 07-17
上海医药：拟挂牌出售上药益药医药（上海）有限公司41%股权
上海医药拟认购3亿元基金份额
美股速递 · 07-17
上海医药拟认购3亿元基金份额
上海医药(02607)拟出资3亿元参设上海生物医药二期基金
智通财经 · 07-17
上海医药(02607)拟出资3亿元参设上海生物医药二期基金
上海医药参与设立上海生物医药二期基金
美股速递 · 07-17
上海医药参与设立上海生物医药二期基金
加载更多
公司概况
公司名称：
上海医药集团股份有限公司
所属行业：
零售业
上市日期：
1994-03-24
主营业务：
上海医药集团股份有限公司的主营业务是医药工业、医药商业。公司的主要产品是麝香保心丸、多糖铁复合物胶囊、胃复春胶囊、双歧杆菌三联活菌制剂、注射用乌司他丁。公司被评为2025《财富》世界500强第407位；《2025年全球医药品牌价值榜》第19位；全球十大最强医药品牌第10位；2025中国企业500强第98位；2025中国制造企业500强第36位；2025年中国医药研发产品线最佳工业企业优秀案例；中国ESG上市公司（2025）先锋100；MSCIESG评级AA级。
发行价格：
4.50
{"stockData":{"symbol":"601607","market":"SH","secType":"STK","nameCN":"上海医药","latestPrice":16.61,"timestamp":1785468596000,"preClose":16.76,"halted":0,"volume":7703618,"delay":0,"changeRate":-0.0089,"floatShares":2789000000,"shares":3708000000,"eps":1.5666,"marketStatus":"午间休市","change":-0.15,"latestTime":"07-31 11:29:56","open":16.7,"high":16.72,"low":16.52,"amount":128000000,"amplitude":0.0119,"askPrice":16.62,"askSize":87,"bidPrice":16.61,"bidSize":15,"shortable":0,"etf":0,"ttmEps":1.5666,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1785474000000},"marketStatusCode":3,"adr":0,"adjPreClose":16.76,"symbolType":"stock","openAndCloseTimeList":[[1785461400000,1785468600000],[1785474000000,1785481200000]],"highLimit":18.44,"lowLimit":15.08,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":3708361809,"isCdr":false,"pbRate":0.8,"roa":"--","peRate":10.602579,"roe":"1.85%","epsLYR":1.54,"committee":0.516539,"marketValue":61596000000,"turnoverRate":0.0028,"status":1,"hkstockBrief":{"symbol":"02607","market":"HK","secType":"STK","nameCN":"上海医药","latestPrice":11.98,"timestamp":1785470700006,"preClose":12.02,"halted":0,"volume":417500,"delay":0,"premium":"-37.96"},"floatMarketCap":46329000000},"requestUrl":"/m/hq/s/601607","defaultTab":"news","newsList":[{"id":"2655782971","title":"上海医药(601607.SH)：瑞舒伐他汀依折麦布片(Ⅰ)获得批准生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2655782971","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655782971?lang=zh_cn&edition=full","pubTime":"2026-07-30 15:59","pubTimestamp":1785398348,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(601607.SH)发布公告，近日，公司下属常州制药厂有限公司(简称“常州制药厂”)收到国家药品监督管理局颁发的关于瑞舒伐他汀依折麦布片(Ⅰ)的《药品注册证书》(证书编号：2026S02581)，该药品获得批准生产。瑞舒伐他汀依折麦布片适用于高胆固醇血症或纯合子型家族性高胆固醇血症(HoFH)，由Sanofi-aventis,S.R.O.公司开发，2014年07月在欧盟上市，商品名为Zenon Neo。2024年12月，常州制药厂有限公司就该药品向国家药监局提出注册上市申请，并获受理。截至公告日，公司针对该药品已投入研发费用约人民币968万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1474036.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0012","BK0099","02607","BK0175","BK0209","BK1197","BK0020","BK0028","BK0097","601607","BK0187","BK0184","BK0183","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655882925","title":"上海医药(601607.SH)：龙虎清凉油经典款等三款产品获加拿大产品许可证","url":"https://stock-news.laohu8.com/highlight/detail?id=2655882925","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655882925?lang=zh_cn&edition=full","pubTime":"2026-07-30 15:57","pubTimestamp":1785398232,"startTime":"0","endTime":"0","summary":"龙虎清凉油经典款、龙虎清凉油强效款、龙虎滚珠风油精这三款产品主要适用于暂时缓解肌肉和关节的酸痛/不适。2026年5月，上药中华向加拿大卫生部天然与非处方健康产品管理局递交产品注册申请。截至本公告日，公司针对前述产品在加拿大上市已投入注册费用约人民币4.95万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1474034.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0097","BK0183","BK0209","BK0175","BK1197","BK0187","BK0196","BK0188","BK0099","BK0028","BK0184","BK0020","BK0012","601607","02607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655890582","title":"股市必读：上海医药（601607）7月29日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2655890582","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655890582?lang=zh_cn&edition=full","pubTime":"2026-07-30 01:35","pubTimestamp":1785346511,"startTime":"0","endTime":"0","summary":"截至2026年7月29日收盘，上海医药报收于16.6元，上涨0.91%，换手率0.45%，成交量12.57万手，成交额2.09亿元。董秘最新回复投资者： 尊敬的董秘，您好！2026年《财富》世界500强企业最新发布，公司是否位列排行之中？2025年公司营业收入2,835.80亿元人民币，同比增长3.03%；实现归属于上市公司股东的净利润57.25亿元人民币，同比上升25.74%。当日关注点交易信息汇总：7月29日上海医药主力资金净流入363.7万元，游资资金净流出1609.35万元，散户资金净流入1245.65万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073000000862.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","BK0012","BK0175","601607","BK0020","02607","BK1197","BK0196","BK0097","BK0184","BK0209","BK0183","BK0028","BK0188","BK0099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655611860","title":"上海医药：2026年第一季度公司药品CSO业务新承接7个品种的商业化合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2655611860","media":"证券日报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655611860?lang=zh_cn&edition=full","pubTime":"2026-07-29 20:00","pubTimestamp":1785326400,"startTime":"0","endTime":"0","summary":"证券日报网7月29日讯，上海医药在接受调研时表示，2026年第一季度，公司药品CSO业务，新承接7个品种的商业化合作，产品矩阵持续优化丰富，为后续业绩增长奠定了扎实基础。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607293825276947.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607293825276947.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0020","BK1197","02607","BK0099","BK0184","BK0209","BK0012","BK0196","BK0187","BK0188","BK0175","BK0097","601607","BK0183","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655860648","title":"上海医药：公司收购上海和黄后，双方整合大品种开发、循证医学研究、中药国际化等核心资源","url":"https://stock-news.laohu8.com/highlight/detail?id=2655860648","media":"证券日报","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655860648?lang=zh_cn&edition=full","pubTime":"2026-07-29 19:58","pubTimestamp":1785326280,"startTime":"0","endTime":"0","summary":"证券日报网7月29日讯，上海医药在接受调研时表示，公司收购上海和黄后，双方依托彼此在产业链和渠道网络等方面的资源优势，整合大品种开发、循证医学研究、中药国际化等核心资源，赋能集团中药业务高质量发展。一方面，公司将借鉴融合上海和黄在中药大品种创新改良方面的丰富经验与管理体系，利用循证医学等手段，加快培育胃复春、八宝丹、冠心宁等系列名优中药品种。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607293825275880.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607293825275880.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02607","BK0183","BK0099","BK0209","BK0012","BK0196","BK0184","BK0097","BK0187","BK0020","BK0188","BK0175","BK0028","601607","BK1197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654020804","title":"上海医药、君实生物等成立新私募基金 出资额15亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2654020804","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654020804?lang=zh_cn&edition=full","pubTime":"2026-07-28 11:18","pubTimestamp":1785208680,"startTime":"0","endTime":"0","summary":"【上海医药、君实生物等成立新私募基金 出资额15亿】天眼查App显示，近日，上海上实生物医药产业私募基金合伙企业（有限合伙）成立，执行事务合伙人为上海上实资本管理有限公司、上海上实生物医药管理咨询有限公司，出资额15亿人民币，经营范围为以私募基金从事股权投资、投资管理、资产管理等活动。合伙人信息显示，该基金由上海国投先导生物医药私募投资基金合伙企业（有限合伙）、上海医药集团股份有限公司、上海君实生物医药科技股份有限公司等共同出资。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607283823297587.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607283823297587.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0099","BK0012","BK0188","BK0184","BK0196","BK0175","BK0097","BK1515","BK1583","BK0020","BK1197","BK0028","BK0187","601607","BK0183","02607","BK1161","BK0209","01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654176095","title":"上海医药2025年三大业务板块毛利率集体下滑遭问询 公司回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2654176095","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654176095?lang=zh_cn&edition=full","pubTime":"2026-07-27 10:13","pubTimestamp":1785118380,"startTime":"0","endTime":"0","summary":"南方财经7月27日电，上交所近日就上海医药(601607.SH)2025年年报下发监管问询函，重点关注公司主营业务三大板块毛利率集体下滑。问询函要求公司补充披露工业、分销、零售板块的产品结构、集采影响及同行业对比情况。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607273821800044.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607273821800044.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0188","BK0183","BK0020","02607","BK0187","BK1197","BK0099","BK0184","BK0175","BK0097","BK0028","BK0196","BK0209","601607","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654068582","title":"出资3亿，上海医药做LP了","url":"https://stock-news.laohu8.com/highlight/detail?id=2654068582","media":"PE星球","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654068582?lang=zh_cn&edition=full","pubTime":"2026-07-26 08:33","pubTimestamp":1785025980,"startTime":"0","endTime":"0","summary":"截至2026年7月25日，上海医药A股总市值为607.43亿元；港股总市值为437.59亿港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzU4MzMxMjMzOQ==&mid=2247547796&idx=2&sn=290a53102392055a5f9e65a3d04d04bc&chksm=fcaf9f7a6a9a78430aab9b558d3aba35dc67bab4606253ce35017e25cb4660966d5d971b0e3e&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["BK0187","BK0012","BK0175","601607","BK0020","BK0196","BK0097","BK0184","BK0209","BK0183","BK0028","BK0188","BK0099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654052272","title":"每周股票复盘：上海医药（601607）终止丹酚酸A临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2654052272","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654052272?lang=zh_cn&edition=full","pubTime":"2026-07-26 01:50","pubTimestamp":1785001823,"startTime":"0","endTime":"0","summary":"截至2026年7月24日收盘，上海医药报收于16.38元，较上周的16.61元下跌1.38%。本周，上海医药7月21日盘中最高价报17.05元。截至公告日，项目累计投入研发费用约800万元人民币。上海医药集团股份有限公司决定终止注射用丹酚酸A的临床试验及后续开发。该项目为中药第1类创新药，拟用于冠心病心绞痛，2016年6月获准开展临床试验，现处II期阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072600000402.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","02607","BK0097","BK1197","BK0184","BK0175","BK0209","BK0099","BK0196","BK0020","BK0028","BK0187","601607","BK0183","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653136038","title":"上海医药（601607）披露参与设立上海上实生物医药产业私募基金暨关联交易进展，7月24日股价下跌1.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2653136038","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653136038?lang=zh_cn&edition=full","pubTime":"2026-07-24 22:16","pubTimestamp":1784902598,"startTime":"0","endTime":"0","summary":"截至2026年7月24日收盘，上海医药报收于16.38元，较前一交易日下跌1.27%，最新总市值为607.43亿元。该股当日开盘16.62元，最高16.69元，最低16.34元，成交额达1.47亿元，换手率为0.32%。近日，上海医药集团股份有限公司发布《关于参与设立上海上实生物医药产业私募基金暨关联/连交易的进展公告》。2026年7月24日，公司已签署《上海上实生物医药产业私募基金合伙企业有限合伙协议》。本次交易构成关联交易。除上述进展外，其他内容与2026年7月18日公告一致。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072400041945.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0020","BK1197","02607","BK0099","BK0184","BK0209","BK0196","BK0187","161726","BK0188","BK0175","BK0097","601607","BK0183","BK0028","399441","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653081246","title":"上海医药(02607)：决定终止注射用丹酚酸A的临床试验及后续开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2653081246","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653081246?lang=zh_cn&edition=full","pubTime":"2026-07-24 19:44","pubTimestamp":1784893480,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(02607)发布公告，为合理配置研发资源、聚焦优势研发项目，公司基于对研发项目未来市场价值、业务协同以及后续开发投入等因素的综合评估，决定终止注射用丹酚酸A的临床试验及后续开发。注射用丹酚酸A是中药1.2类创新药，拟用于冠心病心绞痛。2016年6月，该项目获国家药品监督管理局批准开展临床试验，现处于临床试验II期阶段。截至目前，该项目累计研发投入共计约人民币3743万元。为合理配置研发资源、聚焦优势研发项目，公司基于对该研发项目未来市场价值、业务协同以及后续开发投入等因素的综合评估，决定终止该研发项目的临床试验及后续开发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1472122.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0184","BK0188","BK0097","BK0020","BK0183","BK0175","BK0196","IBBQ","BK0099","PSYK","BK0028","BK0012","BK0187","BMED","IBBJ","601607","BK0209","MDTX","02607","BK1197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653920945","title":"杨鑫鑫2026年二季度表现，工银精选平衡混合基金季度跌幅3.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2653920945","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653920945?lang=zh_cn&edition=full","pubTime":"2026-07-21 23:42","pubTimestamp":1784648548,"startTime":"0","endTime":"0","summary":"证券之星消息，截止2026年二季度末，基金经理杨鑫鑫旗下共管理2只基金，本季度表现最佳的为工银精选平衡混合，季度净值跌3.96%。持有期间的估算收益率为87.53%，持有期间中航光电在2020年到2021年的年报归属净利润增幅达38.35%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072100045942.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0184","BK0187","BK0028","BK0209","BK0183","BK0012","BK0188","BK0175","BK0196","BK0097","BK0099","601607","BK0020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653105842","title":"股市必读：上海医药（601607）7月20日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2653105842","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653105842?lang=zh_cn&edition=full","pubTime":"2026-07-21 01:21","pubTimestamp":1784568069,"startTime":"0","endTime":"0","summary":"截至2026年7月20日收盘，上海医药报收于16.92元，上涨1.87%，换手率0.81%，成交量22.55万手，成交额3.78亿元。董秘最新回复投资者： 董秘您好。公司公告汇总：上海医药下属上药中药所研发的清润养目颗粒获国家药监局临床试验批准，为中药1.1类创新药，累计研发投入约800万元，尚未在国内外上市。交易信息汇总资金流向7月20日主力资金净流入659.02万元，占总成交额0.0%；游资资金净流出3627.75万元，占总成交额0.0%；散户资金净流入2968.74万元，占总成交额0.0%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072100001242.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","BK0012","BK0175","601607","BK0020","02607","BK1197","BK0196","BK0097","BK0184","BK0209","BK0183","BK0028","BK0188","BK0099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652229423","title":"上海医药：双靶点CAR-T产品B019Ⅰ期临床试验正有序推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2652229423","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652229423?lang=zh_cn&edition=full","pubTime":"2026-07-20 18:00","pubTimestamp":1784541643,"startTime":"0","endTime":"0","summary":"证券之星消息，上海医药07月20日在投资者关系平台上答复投资者关心的问题。上海医药旗下上药生物治疗积极布局CGT赛道，目前公司在研管线中，双靶点CAR-T产品B019针对儿童急性淋巴细胞白血病、成人非霍奇金淋巴瘤两大适应症的Ⅰ期临床试验，目前正按计划有序推进，另一款自主研发的通用型iNKT细胞治疗产品B023已获批临床。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072000028087.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0099","BK0028","BK0187","02607","BK0184","BK0209","BK0020","BK0175","601607","BK0196","BK0183","BK0188","BK1197","BK0097","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652953372","title":"上海医药(601607.SH)下属公司清润养目颗粒获批开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2652953372","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652953372?lang=zh_cn&edition=full","pubTime":"2026-07-20 15:59","pubTimestamp":1784534392,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(601607.SH)发布公告，近日，公司下属上海医药集团中药研究所有限公司(简称“上药中药所”)研发的“清润养目颗粒”收到国家药品监督管理局核准签发的《药物临床试验批准通知书》。清润养目颗粒是在成都中医药大学附属医院院内制剂清润养目口服液基础上变更工艺和剂型研制而成。该项目由上药中药所与成都中医药大学附属医院等单位合作研发，并拥有核心知识产权。该药品拟开展用于干眼的临床试验。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469719.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IBBQ","BK0028","BK0196","BK0183","BK0012","BK0020","BMED","BK0209","BK1197","BK0187","BK0175","BK0099","BK0184","601607","BK0097","02607","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652472237","title":"每周股票复盘：XD上海医（601607）上海医药拟出资3亿参与设立生物医药基金","url":"https://stock-news.laohu8.com/highlight/detail?id=2652472237","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652472237?lang=zh_cn&edition=full","pubTime":"2026-07-19 01:37","pubTimestamp":1784396228,"startTime":"0","endTime":"0","summary":"截至2026年7月17日收盘，XD上海医报收于16.61元，较上周的16.13元上涨2.98%。本周关注点来自公司公告汇总：上海医药拟作为有限合伙人出资3亿元参与设立上海上实生物医药产业私募基金。会议审议通过《关于参与设立上海上实生物医药产业私募基金暨关联/连交易的议案》，公司作为有限合伙人出资3亿元参与设立该基金，关联董事杨秋华回避表决，9名非关联董事全票通过。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071900000306.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0012","BK0175","BK0099","BK0184","160635","02607","BK0097","BK0183","BK1197","BK0028","BK0020","601607","BK0188","BK0187","BK0209"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652283168","title":"上海医药：拟挂牌出售上药益药医药（上海）有限公司41%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2652283168","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652283168?lang=zh_cn&edition=full","pubTime":"2026-07-17 20:40","pubTimestamp":1784292048,"startTime":"0","endTime":"0","summary":"上海医药(601607.SH)公告称，公司下属上药控股拟通过产权交易所以公开挂牌方式转让所持控股子公司上药益药医药（上海）有限公司（简称“标的公司”）41%股权，挂牌转让价格拟定为3.3亿元。本次交易完成后，上海医药通过上药控股将持有标的公司10%股权，不再对标的公司实施并表。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700041814.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09939","BK1574","BK0188","BK1197","BK0097","BK0196","BK0209","BK0099","BK0020","BK0175","BK1161","BK0184","02607","BK0012","BK0183","BK1515","159938","601607","BK0187","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137799396","title":"上海医药拟认购3亿元基金份额","url":"https://stock-news.laohu8.com/highlight/detail?id=1137799396","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137799396?lang=zh_cn&edition=full","pubTime":"2026-07-17 20:18","pubTimestamp":1784290739,"startTime":"0","endTime":"0","summary":"上海医药集团股份有限公司宣布，计划认购一只基金的人民币3亿元资本承诺份额。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0196","BK0012","BK0020","BK0028","BK0184","BK0187","BK0209","BK0183","BK0175","BK0099","BK0188","BK0097","601607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652628877","title":"上海医药(02607)拟出资3亿元参设上海生物医药二期基金","url":"https://stock-news.laohu8.com/highlight/detail?id=2652628877","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652628877?lang=zh_cn&edition=full","pubTime":"2026-07-17 20:18","pubTimestamp":1784290689,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药 公布，于 2026 年 7 月 17 日，董事会已批准公司参与设立上海生物医药二期基金。公司参与组建并设立上海生物医药二期基金，对上海市生物医药产业及公司未来的高质量发展具有重大战略意义。上海生物医药二期基金将成为推动公司创新体系建设及“大BD”战略目标的重要工具，旨在构建一个涵盖“发现、转化、落地”等多维协同的内部闭环生态。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469240.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0099","BK4581","399441","BK0012","BK0188","BK0184","161726","BK4588","BK0196","BK0175","BK0097","XBI","BK0020","BK1197","BK0028","BK0187","601607","BK0183","02607","BK4585","BK0209"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194537371","title":"上海医药参与设立上海生物医药二期基金","url":"https://stock-news.laohu8.com/highlight/detail?id=1194537371","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194537371?lang=zh_cn&edition=full","pubTime":"2026-07-17 20:16","pubTimestamp":1784290580,"startTime":"0","endTime":"0","summary":"上海医药集团股份有限公司宣布，将参与设立上海生物医药二期基金。此举旨在进一步布局生物医药产业，通过资本纽带整合行业资源，推动创新项目孵化与成长。公司此举有望强化其在医药研发及投资领域的战略协同效应，为长远发展注入新动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0028","BK0184","BK0175","BK0188","BK0012","BK0099","BK0183","601607","BK0187","BK0209","BK0196","BK0020","BK0097"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1785472679996,"stockEarnings":[{"period":"1week","weight":0.0102},{"period":"1month","weight":0.1112},{"period":"3month","weight":0.0013},{"period":"6month","weight":-0.0109},{"period":"1year","weight":-0.1096},{"period":"ytd","weight":-0.0354}],"compareEarnings":[{"period":"1week","weight":-0.0186},{"period":"1month","weight":-0.0708},{"period":"3month","weight":-0.0748},{"period":"6month","weight":-0.0761},{"period":"1year","weight":0.0523},{"period":"ytd","weight":-0.0414}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海医药集团股份有限公司","boardCode":"AI0052","boardName":"零售业","stockholders":"100447人(较上一季度增加Infinity%)","perCapita":"27767股","listingDate":"1994-03-24","address":"上海市浦东新区中国(上海)自由贸易试验区张江路92号","registeredCapital":"370836万元","survey":" 上海医药集团股份有限公司的主营业务是医药工业、医药商业。公司的主要产品是麝香保心丸、多糖铁复合物胶囊、胃复春胶囊、双歧杆菌三联活菌制剂、注射用乌司他丁。公司被评为2025《财富》世界500强第407位；《2025年全球医药品牌价值榜》第19位；全球十大最强医药品牌第10位；2025中国企业500强第98位；2025中国制造企业500强第36位；2025年中国医药研发产品线最佳工业企业优秀案例；中国ESG上市公司（2025）先锋100；MSCIESG评级AA级。","listedPrice":4.5},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"上海医药(601607)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供上海医药(601607)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"上海医药,601607,上海医药股票,上海医药股票老虎,上海医药股票老虎国际,上海医药行情,上海医药股票行情,上海医药股价,上海医药股市,上海医药股票价格,上海医药股票交易,上海医药股票购买,上海医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"上海医药(601607)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供上海医药(601607)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}